Key points are not available for this paper at this time.
Because of a warning from the FDA, 23andMe has stopped marketing its personal genome service. Now, a dialogue about key issues in genomic testing could result in clear standards for the industry, including requirements for informed consent and disclosure of results.
Annas et al. (Wed,) studied this question.